The current outbreak of respiratory disease (SARS CoV-2) caused by the novel coronavirus (2019nCoV) began in late December 2019 in Wuhan, China. Nearly three years later, SARS CoV-2 transmission remains high, partly due to the emergence of multiple variant strains of the virus. The World Health Organization (WHO) situation report from late November identified 634,522,052…
This paper presents the result from a randomised, double-blind study in adults with sore throat due to upper respiratory tract infection who took flurbiprofen (n = 249) or placebo spray (n = 256). Pain relief was assessed using the Sore Throat Relief Rating Scale. In this study, flurbiprofen spray provided significantly greater relief versus placebo…
Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity. In 2 randomised clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months apart. In this post-hoc analysis, the efficacy of RZV against HZ and postherpetic neuralgia (PHN) were investigated by sex, geographic region, and geographic…
The ZOE-50 and ZOE-70 phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. This article presents a comprehensive overview of the safety data from these studies. Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses…
